IART

Integra is a quality franchise on paper — world leader in neurosurgery, ~70% of revenue in the Codman Specialty Surgical segment, 52.0% gross margin — but the income statement has deteriorated relentlessly. Net income has gone from $169M (FY2021) to $181M, $67.7M, -$6.94M, and now -$516M in FY2025, with operating income swinging to -$493M (-30.2% operating margin) and diluted EPS at -$6.74. Revenue is barely growing (+1.5% to $1.64B), so this is not a top-line story masking a turnaround; it is flat sales against a profitability and returns collapse (ROE -49.5%). Stockholders' equity fell 32.5% to $1.04B and retained earnings dropped 54.9%, consistent with large impairment/charge-driven losses rather than a clean operating year.

The filing makes the balance sheet the central risk. Management states it 'expect[s] to seek to refinance all of our outstanding debt in 2026,' and the Consolidated Total Leverage Ratio sits at 4.50 against a covenant of 5.00 — but that covenant steps down to 4.75 for the quarter ending September 30, 2026, leaving only ~0.25x of headroom just as earnings are weakest. The $575.0M 2025 Notes were settled at maturity in cash funded by drawing on the revolving credit facility, shifting bond debt onto the revolver and increasing reliance on the bank line ahead of a full refinancing. Long-term debt is $727M, liabilities/equity is 2.45x, and operating cash flow fell 61.1% to $50.4M — less than FY2025 capex of $81.4M, so the business did not self-fund its investment this year. Cash is only $235M.